CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...